icad inc. (ICAD) News



icad inc. (ICAD)

Today's Latest Price: $13.30 USD

0.26 (1.99%)

Updated Jan 19 4:00pm

Add ICAD to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 185 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

StocksNews Articles for ICAD

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ICAD News From Around the Web

Below are the latest news stories about Icad Inc that investors may wish to consider to help them evaluate ICAD as an investment opportunity.

iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

New ProFound AI risk software, offering a 2-year projected risk score to be featuredNASHUA, N.H., Jan. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021. Michael Klein, Chairman and CEO, will host 1x1 meetings and will participate in a panel, Innovations in Cancer Diagnostics, on Thursday, January 7th at 4pm EST.Mr. Klein’s focus in diagnostics will be on iCAD’s newly launched ProFound AI Risk offering. This new breast cancer screening capability is the first and only commercially available clinical decision support tool that provides an accurate 2-year risk ...

Yahoo | January 6, 2021

iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption

International Multi-Center Study to Commence January 2021 University of Louisville’s Trial on IORT for Large Brain Lesion Treatments Accelerating First European Patient Treated for Brain Metastasis with Xoft IORT System NASHUA, N.H., Dec. 29, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Santosh Kesari, MD, PhD, a world-renowned neuro-oncologist, as Principal Investigator of its International multi-center clinical trial evaluating the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® as the sole radiation therapy to treat recurrent glioblastoma (GBM) following surgical excision of the malignancy. The study is planned to commence in January 2021 at...

Yahoo | December 29, 2020

What Percentage Of iCAD, Inc. (NASDAQ:ICAD) Shares Do Insiders Own?

A look at the shareholders of iCAD, Inc. ( NASDAQ:ICAD ) can tell us which group is most powerful. Insiders often own a...

Yahoo | December 23, 2020

Is ICAD A Good Stock To Buy Now?

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

Yahoo | December 13, 2020

Solis Mammography Adopts iCAD’s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution

Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services’ NetworkNASHUA, N.H. and DALLAS, Dec. 10, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and Solis Mammography, the largest independent provider of mammography and breast health services in the United States, today announced a five-year partnership whereby iCAD will provide Solis Mammography’s nationwide network with its latest artificial intelligence (AI) breast health solutions, including ProFound AI® for DBT and ProFound AI Risk, the first and only clinical decision support tool to provide an accurate two-year breast ca...

Yahoo | December 10, 2020

iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020

Groundbreaking ProFound AI Risk Helps Transform Breast Cancer Screening from an Age-Based Paradigm to Risk-Adapted Precision Screening, Individualized for Each WomanNASHUA, N.H., Nov. 30, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company is showcasing its leading Breast Health Solutions, including the expanded ProFound AI® platform powered by Panorama, at the 106th Scientific Assembly and virtual Annual Meeting of the Radiological Society of North America (RSNA), November 29 – December 5. The Company’s full suite of solutions includes the latest generation of ProFound AI for Digital Breast Tomosynthesis (DBT), the first artificial intelligence (AI) cancer d...

Yahoo | November 30, 2020

iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress

Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer TypesNASHUA, N.H., Nov. 25, 2020 (GLOBE NEWSWIRE) --  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that researchers from Miguel Servet University Hospital in Zaragoza, Spain, will present new data from three clinical studies supporting the efficacy of the expanded Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast and endometrial cancers during the European Society for Radiotherapy & Oncology (ESTRO) 2020 meeting held virtually November 28 through December 1. The Company will highlight the latest technology for the expanded Xoft platform, including its full suite of applicators for...

Yahoo | November 25, 2020

iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales

Significant Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and Fuji ProFound AI for DBT Offers Superior Clinical Performance When Compared to Other Commercially Available Breast AI Systems NASHUA, N.H., Nov. 24, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported that over 1,000 licenses have been sold as part of ProFound AI® sales since the products were launched, signaling the rapid and wide-spread adoption of the pioneering cancer detection software solution built on artificial intelligence (AI). The sales have been distributed across all major mammography system vendors and enterprise-wide viewing applications ...

Yahoo | November 24, 2020

Analysts Have Made A Financial Statement On iCAD, Inc.'s (NASDAQ:ICAD) Third-Quarter Report

iCAD, Inc. (NASDAQ:ICAD) just released its latest quarterly results and things are looking bullish. iCAD outperformed...

Yahoo | November 8, 2020

Icade’s (CDMGF) Hold Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reissued their hold rating on shares of Icade (OTCMKTS:CDMGF) in a research note issued to investors on Friday, The Fly reports. Other equities research analysts have also recently issued research reports about the stock. Bank of America raised shares of Icade from a neutral rating to a buy rating in a research […]

Dakota Financial News | October 24, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7675 seconds.